XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2022
Stockholders' Equity Note [Abstract]  
Stock-based Compensation Expense
The stock-based compensation related to our stock-based awards and employee stock purchase plan for the three and six months ended June 30, 2022 and 2021 is as follows (in thousands):
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2022202120222021
Cost of net revenues$1,614 $1,418 $3,128 $2,724 
Selling, general and administrative26,491 23,058 51,216 44,902 
Research and development6,035 4,379 11,417 8,470 
Total stock-based compensation$34,140 $28,855 $65,761 $56,096 
Summary Of Restricted Stock Units A summary for the six months ended June 30, 2022 is as follows:
Number of Shares
Underlying RSUs
(in thousands)
Weighted Average Grant Date Fair ValueWeighted Average Remaining
Contractual Term (in years)
Aggregate
Intrinsic Value
(in thousands)
Unvested as of December 31, 2021492 $369.17 
Granted
232 485.01 
Vested and released(189)333.28 
Forfeited(22)429.13 
Unvested as of June 30, 2022513 $432.28 1.6$121,475 
Summary Of Market-performance Based Restricted Stock Units
The following table summarizes the MSU performance for the six months ended June 30, 2022: 
Number of Shares
Underlying MSUs
(in thousands)
Weighted Average Grant Date Fair Value
Weighted Average
Remaining
Contractual Term (in years)
Aggregate
Intrinsic Value
(in thousands)
Unvested as of December 31, 2021174 $551.57 
Granted 1
101 607.96 
Vested and released(128)396.10 
Forfeited(3)744.39 
Unvested as of June 30, 2022144 $725.73 1.5$34,097 
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions
The fair value of the option component of the 2010 Purchase Plan shares was estimated at the grant date using the Black-Scholes option pricing model with the following weighted average assumptions:
 Six Months Ended
June 30,
 20222021
Expected term (in years)1.51.0
Expected volatility48.6 %58.8 %
Risk-free interest rate1.0 %0.1 %
Expected dividends— — 
Weighted average fair value at grant date$196.97 $202.74